Novel intestinal dialysis interventions and microbiome modulation to control uremia

Area of Science:

• Nephrology
• Gastroenterology
• Microbiome Research

Background:

• The gut is crucial for fluid/electrolyte balance and uremic toxin management in chronic kidney disease (CKD).
• Uremic toxins and electrolyte imbalances significantly impact CKD progression and patient outcomes.

Purpose of the Study:

• To review current evidence on gut-targeted interventions for managing uremia, fluid overload, hyperkalemia, and hyperphosphatemia in CKD.
• To explore novel therapeutic strategies focusing on the gut microbiome and enhanced bowel elimination.

Main Methods:

• Review of emerging studies on intestinal dialysis (colonic perfusion, irrigation).
• Analysis of oral adsorbents (e.g., AST-120) for reducing uremic toxins.
• Evaluation of dietary interventions (plant-based, low-protein) and pre/pro/synbiotics.
• Assessment of methods to modulate gut microbiota and enhance bowel elimination.

Main Results:

• Intestinal dialysis shows preliminary promise as an adjuvant therapy for uremia in CKD.
• Oral adsorbent AST-120 reduces key uremic toxins (indoxyl sulfate, p-cresol sulfate) with potential renoprotective effects.
• Dietary changes and gut microbiota modulation may reduce uremic toxin generation.
• Inducing diarrhea can potentially manage fluid and electrolyte load.

Conclusions:

• Gut-targeted interventions offer novel therapeutic avenues for managing CKD complications.
• Modulating the gut microbiome and enhancing toxin elimination are key strategies.
• Further clinical trials are needed to confirm the efficacy of these interventions on kidney and cardiovascular outcomes.